Search Results for "Stalevo"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Stalevo. Results 1 to 3 of 3 total matches.
See also: entacapone, levodopa
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
/100/200, 300-1500 mg levodopa/day, divided
generic 31.25/125/200, 37.5/150/200, 272.10
Stalevo ...
The FDA has approved opicapone (Ongentys –
Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an
adjunct to carbidopa/levodopa in adults with Parkinson’s
disease (PD) who experience "off" episodes. It is the
third COMT inhibitor to be approved for this indication;
tolcapone (Tasmar, and generics) and entacapone
(Comtan, and generics) were approved earlier. Opicapone
has been available in Europe since 2016.
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
278.10
Stalevo (Orion) 25/100/200, 31.25/125/200, 688.20
37.5/150/200, 50/200/200 mg tabs
MAO-B ...
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor symptoms
of the disease are thought to be caused by degeneration of
other neurotransmitter systems. No disease-modifying
drugs are available for treatment of PD.
Comparison Table: Drugs for Parkinson's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
6212.80
10,668.50
Carbidopa/levodopa/entacapone –
generic
Stalevo (Orion)
12.5/50/200,
18.75/75/200 ...
View the Comparison Table: Drugs for Parkinson's Disease